Outlook Therapeutics Announces Resubmission of Biologics License Application to U.S. FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg)
Outlook Therapeutics (Nasdaq: OTLK) resubmitted its Biologics License Application to the U.S. FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg) to treat neovascular age-related macular degeneration (nAMD).
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Outlook Therapeutics (Nasdaq: OTLK) resubmitted its Biologics License Application to the U.S. FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg) to treat neovascular age-related macular degeneration (nAMD). The FDA Office of New Drugs concluded substantial evidence of effectiveness and indicated no additional trials are required.
The resubmission is designated a Class 1 review, with a PDUFA decision expected within 60 days of FDA receipt, and interactions now focusing on final product labeling.
Positive
- FDA Office of New Drugs found substantial evidence of effectiveness for nAMD
- No additional clinical trials required for ONS-5010/LYTENAVA™ BLA
- Class 1 resubmission with PDUFA decision expected within 60 days
Negative
- Product still awaits FDA approval before any U.S. commercialization
- Previous FDA Complete Response Letter required appeal and resubmission
Details
News Market Reaction – OTLK
On Jun 1, the day this news came out, OTLK closed 15.48% above the previous close.
Data tracked by StockTitan Argus for the Jun 1 session.
Key Figures
- PDUFA timeline
- 60 days
- Class 1 BLA resubmission review window after FDA receipt
- Registered direct shares
- 8,539,709 shares
- May 2026 registered direct offering to GMS Ventures
- Offering price
- $0.5855 per share
- Price for May 2026 registered direct offering
- Expected gross proceeds
- $5.0 million
- May 2026 registered direct offering before expenses
- Net loss
- $4.5 million
- Net loss attributable to common stockholders, Q2 FY2026
- Adjusted net loss
- $14.1 million
- Non-GAAP adjusted net loss, Q2 FY2026
- Cash balance
- $7.7 million
- Cash and cash equivalents as of March 31, 2026
- Q2 revenue
- $128,000
- Quarterly revenues reported for Q2 FY2026
Historical Context
-
FDA Office of New Drugs granted appeal, confirming substantial evidence of effectiveness.
-
Q2 FY2026 loss narrowed year over year; European commercialization and FDA decision timing updated.
-
Closed $5.0M registered direct at $0.31 with additional warrant financing potential.
-
Announced $5.0M registered direct offering and concurrent warrants for up to 16,129,033 shares.
-
Completed FDA Federal Dispute Resolution meeting; awaiting formal response in May 2026.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
biologics license application regulatory
complete response letter regulatory
pdufa regulatory
pharmacovigilance medical
anti-VEGF medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
ISELIN, N.J., June 01, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal diseases, today announced the resubmission of its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ONS-5010/LYTENAVA™ for the treatment of neovascular age-related macular degeneration (nAMD).
As previously announced, Outlook Therapeutics successfully appealed the December 2026 Complete Response Letter (CRL) related to the ONS-5010 Biologics License Application reviewed by the FDA. In their decision, the FDA Office of New Drugs concluded that substantial evidence of effectiveness has been established for LYTENAVA™ for the treatment of neovascular age-related macular degeneration (nAMD), therefore additional trials are not required.
The FDR decision directed the Division of Ophthalmology and Office of Specialty Medicine to work with Outlook Therapeutics to focus on reaching an agreement on final product labeling. Additionally, as indicated in the formal decision, this will be a Class 1 resubmission with a PDUFA date and decision expected within 60 days of FDA’s receipt of the resubmission.
Dr. Baruch Kuppermann, Steinert Endowed Professor, Chair, Dept of Ophthalmology and Visual Sciences, Director, Gavin Herbert Eye Institute University of California, Irvine, stated, “ONS-5010/LYTENAVA™ has the potential to offer clinicians and patients an important additional option for treating wet AMD. If approved as the first on-label ophthalmic formulation of bevacizumab, ONS-5010 will enable patients to benefit from wider access and provide an attractive alternative for anti-VEGF treatment of wet AMD.”
“We are incredibly pleased to reach this important milestone. This resubmission represents the strength of our application and the tremendous dedication of our entire organization,” said Bob Jahr, Chief Executive Officer of Outlook Therapeutics. “Our team worked through an extensive and rigorous review and appeal process, maintaining close collaboration with the FDA. We are encouraged with the Class 1 review designation. We remain committed to bringing ONS-5010/LYTENAVA™ to patients who deserve FDA-approved options for the treatment of nAMD.”
When approved, ONS-5010/LYTENAVA™ will be the first and only FDA-approved ophthalmic formulation of bevacizumab supported by standardized manufacturing, FDA-approved labeling, and robust pharmacovigilance.
About ONS-5010 / LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma)
ONS-5010/LYTENAVA™ is an ophthalmic formulation of bevacizumab produced in the United States for the treatment of wet AMD. LYTENAVA™ (bevacizumab gamma) is the subject of a centralized Marketing Authorization granted by the European Commission in the EU and Marketing Authorization granted by the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK for the treatment of wet AMD. In certain European Union Member States, ONS-5010/LYTENAVA™ must receive pricing and reimbursement approval before it can be sold.
In the United States, ONS-5010/LYTENAVA ™ (bevacizumab-vikg) is investigational. When approved, it will be the first ophthalmic formulation approved by the FDA.
Bevacizumab-vikg (bevacizumab gamma in the EU and UK) is a recombinant humanized monoclonal antibody (mAb) that selectively binds with high affinity to all isoforms of human vascular endothelial growth factor (VEGF) and neutralizes VEGF’s biologic activity through a steric blocking of the binding of VEGF to its receptors Flt-1 (VEGFR-1) and KDR (VEGFR-2) on the surface of endothelial cells. Following intravitreal injection, the binding of bevacizumab to VEGF prevents the interaction of VEGF with its receptors on the surface of endothelial cells, reducing endothelial cell proliferation, vascular leakage, and new blood vessel formation in the retina.
About Outlook Therapeutics, Inc.
Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma). LYTENAVA™ (bevacizumab gamma) is the first ophthalmic formulation of bevacizumab to receive European Commission and MHRA Marketing Authorization for the treatment of wet AMD. Outlook Therapeutics commenced commercial launch of LYTENAVA™ (bevacizumab gamma) in Germany, Austria, and the UK as a treatment for wet AMD.
Forward-Looking Statements
This press release contains statements that may or are considered “forward-looking statements”. All statements other than statements of historical facts are “forward-looking statements,” including those relating to future events. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “believe,” “can,” “could,” “continue,” “expect,” “may,” “on track,” “plan,” “potential,” “target,” “will,” or “would”, the negative of terms like these or other comparable terminology, and other words or terms of similar meaning. These include, among others, plans for continued engagement with the FDA and the potential to agree on a regulatory pathway for ONS-5010, the potential of ONS-5010/LYTENAVA™ as a treatment for wet AMD, the potential for ONS-5010 to receive approval from the FDA, and other statements that are not historical fact. Although Outlook Therapeutics believes that it has a reasonable basis for the forward-looking statements contained herein, they are based on current expectations about future events affecting Outlook Therapeutics and are subject to risks, uncertainties, and factors relating to its operations and business environment, all of which are difficult to predict and many of which are beyond its control. These risk factors include those risks associated with developing and commercializing pharmaceutical product candidates, risks in obtaining necessary regulatory approvals, the content and timing of decisions by regulatory bodies, as well as those risks detailed in Outlook Therapeutics’ filings with the Securities and Exchange Commission (the SEC), including the Annual Report on Form 10-K for the fiscal year ended September 30, 2025, filed with the SEC on December 19, 2025, as supplemented by the Quarterly Report on Form 10-Q for the fiscal quarter ended December 31, 2025 and future reports Outlook Therapeutics files with the SEC, which include uncertainty of market conditions and future impacts related to macroeconomic factors, including as a result of the ongoing overseas conflicts, tariffs, and trade tensions, fluctuations in interest rates and inflation, and potential future bank failures on the global business environment. These risks may cause actual results to differ materially from those expressed or implied by forward-looking statements in this press release. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Outlook Therapeutics does not undertake any obligation to update, amend, or clarify these forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required under applicable securities law.
Investor Inquiries:
Jenene Thomas
Chief Executive Officer
JTC Team, LLC
T: 908.824.0775
OTLK@jtcir.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.